Opinion
Video
Author(s):
Key opinion leaders summarize their main insights and key takeaways from the EHA 2024 conference regarding advances in lower-risk myelodysplastic syndrome treatment.
Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment
Perioperative Durvalumab Regimen Upholds EFS Benefit in Resectable NSCLC
Dr Le on SOHO-01 Data With BAY 2927088 in HER2-Mutated NSCLC
Adjuvant Alectinib Is Associated With a Tolerable Safety Profile in ALK+ NSCLC
Tarlatamab Sustains Responses, Shows Long-Term Tolerability in Heavily Pretreated SCLC